Free tool
FAERS Monitor: Genvoya
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207561 or its brand name (Genvoya, Cobicistat, Elvitegravir, Emtricitabine, Tenofovir Alafenamide Fumarate). Reports on generic versions are filed under their own applications.
Reports
10,045
Serious
7,813
78% of reports
Hospitalization
1,145
Death reported
199
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- bone density decreased4,545
- chronic kidney disease2,641
- bone loss2,432
- osteonecrosis2,397
- tooth loss2,280
- multiple fractures2,144
- renal failure2,119
- osteoporosis1,952
- renal injury1,931
- pain1,867
- emotional distress1,812
- skeletal injury1,662
- anxiety1,644
- anhedonia1,570
- osteopenia1,212
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 3 |
| 2016 | 242 |
| 2017 | 524 |
| 2018 | 812 |
| 2019 | 1,136 |
| 2020 | 4,082 |
| 2021 | 1,336 |
| 2022 | 783 |
| 2023 | 358 |
| 2024 | 378 |
| 2025 | 302 |
| 2026 | 89 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,114 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bone lossSignal | 2,432 | 403.9 | 388.5 | 819,610 |
| skeletal injurySignal | 1,662 | 400.7 | 381.6 | 556,160 |
| bone density decreasedSignal | 4,545 | 355.0 | 346.4 | 1,373,741 |
| multiple fracturesSignal | 2,144 | 314.1 | 301.5 | 582,089 |
| tooth lossSignal | 2,280 | 258.5 | 248.7 | 520,953 |
| osteopeniaSignal | 1,212 | 181.7 | 171.9 | 200,349 |
| osteonecrosisSignal | 2,397 | 164.7 | 158.8 | 362,081 |
| renal injurySignal | 1,931 | 145.5 | 139.5 | 259,281 |
| anhedoniaSignal | 1,570 | 133.0 | 126.8 | 193,471 |
| osteoporosisSignal | 1,952 | 104.3 | 100.1 | 190,455 |
| chronic kidney diseaseSignal | 2,641 | 75.4 | 72.9 | 187,661 |
| renal failureSignal | 2,119 | 33.9 | 32.7 | 67,047 |
| emotional distressSignal | 1,812 | 31.8 | 30.5 | 53,523 |
| anxietySignal | 1,644 | 12.2 | 11.6 | 16,959 |
| painSignal | 1,867 | 6.4 | 6.1 | 8,694 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.